Skip to main content

Table 1 Patient characteristics (full analysis set)

From: A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients

  Placebo (n = 195) Duloxetine (n = 191) p Value
Age, yr 49.5 ± 11.7 47.8 ± 12.0 0.1373a
Females 164 (84.1) 157 (82.2) 0.6837
Weight, kg 56.28 ± 10.47 58.00 ± 11.23 0.1219a
Height, cm 159.61 ± 7.76 159.41 ± 7.40 0.7922
Major depressive disorder diagnosis 7 (3.6) 8 (4.2) 0.7980
Duration of fibromyalgia, yr 5.7 ± 6.6 5.5 ± 5.9 0.6968
Number of tender points 15.5 ± 2.3 15.4 ± 2.3 0.8740
BPI average pain score (0–10) 6.13 ± 1.35 6.05 ± 1.29 0.5456
FIQ total score (0–100) 56.82 ± 16.14 55.95 ± 16.25 0.5950
BDI-II total score (0–63) 14.89 ± 9.62 15.34 ± 9.73 0.6533
  1. BDI-II Beck Depression Inventory II, BPI Brief Pain Inventory, FIQ Fibromyalgia Impact Questionnaire
  2. Values are means ± standard deviation or n (%). Continuous variables were analyzed using Welch’s t test, and categorical variables were analyzed using Fisher’s exact test
  3. aStatistically significant at a two-sided significance level of 0.15